share_log

Lyell Immunopharma Analyst Ratings

Lyell Immunopharmaアナリストレーティング

Benzinga ·  2023/08/28 04:47
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating
08/28/2023 118.34% JP Morgan $15 → $5 Downgrades Overweight → Neutral
05/05/2023 293.01% HC Wainwright & Co. → $9 Reiterates → Buy
03/02/2023 293.01% HC Wainwright & Co. $11 → $9 Maintains Buy
01/24/2023 74.67% Morgan Stanley $7 → $4 Maintains Equal-Weight
11/14/2022 205.68% Morgan Stanley $15 → $7 Downgrades Overweight → Equal-Weight
11/11/2022 Goldman Sachs Downgrades Buy → Neutral
10/17/2022 424.02% HC Wainwright & Co. → $12 Initiates Coverage On → Buy
05/24/2022 424.02% Goldman Sachs $21 → $12 Maintains Buy
03/31/2022 817.03% Goldman Sachs $31 → $21 Maintains Buy
01/06/2022 773.36% Morgan Stanley $25 → $20 Maintains Overweight
07/12/2021 991.7% Morgan Stanley → $25 Initiates Coverage On → Overweight
07/12/2021 991.7% B of A Securities → $25 Initiates Coverage On → Buy
07/12/2021 860.7% JP Morgan → $22 Initiates Coverage On → Overweight
07/12/2021 1210.04% Goldman Sachs → $30 Initiates Coverage On → Buy

What is the target price for Lyell Immunopharma (LYEL)?

The latest price target for Lyell Immunopharma (NASDAQ: LYEL) was reported by JP Morgan on August 28, 2023. The analyst firm set a price target for $5.00 expecting LYEL to rise to within 12 months (a possible 118.34% upside). 7 analyst firms have reported ratings in the last year.

What is the most recent analyst rating for Lyell Immunopharma (LYEL)?

The latest analyst rating for Lyell Immunopharma (NASDAQ: LYEL) was provided by JP Morgan, and Lyell Immunopharma downgraded their neutral rating.

When is the next analyst rating going to be posted or updated for Lyell Immunopharma (LYEL)?

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Lyell Immunopharma, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Lyell Immunopharma was filed on August 28, 2023 so you should expect the next rating to be made available sometime around August 28, 2024.

Is the Analyst Rating Lyell Immunopharma (LYEL) correct?

While ratings are subjective and will change, the latest Lyell Immunopharma (LYEL) rating was a downgraded with a price target of $15.00 to $5.00. The current price Lyell Immunopharma (LYEL) is trading at is $2.29, which is out of the analyst's predicted range.

これらの内容は、情報提供及び投資家教育のためのものであり、いかなる個別株や投資方法を推奨するものではありません。 更に詳しい情報
    コメントする